📜 What This Document Is 📜

This document is a definitive Proxy Statement (DEF 14A). 👉 Essentially, it is a mandatory annual report designed to inform the company's stockholders about the key decisions and issues that will be voted on at the Annual Meeting of Stockholders.

• Purpose: The filing provides all the necessary details for shareholders to vote their shares on important matters, such as electing directors and approving the company’s independent auditor.
• Meeting Details: The Annual Meeting is scheduled for June 3, 2026, at 10:00 a.m. Eastern Time, and will be held virtually.
• Source: The statement is filed by Bioventus Inc., Inc. (BVS), and was filed on April 22, 2026.

🏢 What Bioventus Inc. Does 🧬

Bioventus is a medical technology company focused on developing and commercializing products for advanced wound care and other healing technologies. 👉 The company positions itself in the healthcare field, helping patients recover and lead active lives by improving wound healing and providing other necessary medical solutions.

• Core Focus: The company has established market-leading products in its core businesses while also focusing on new, high-growth areas of its portfolio.
• Growth Initiatives: Bioventus is actively advancing future growth drivers, such as pilot launches for its Peripheral Nerve Stimulation products for chronic pain and its Platelet Rich Plasma product.
• Revenue Driver: The company states that its growth trajectory is supported by both these established core businesses and its targeted investments in new product areas.

🚀 CEO's Strategic Outlook for 2026 📈

Robert E. Claypoole, the President and CEO, begins the statement with a highly positive outlook, detailing the company's performance in 2025 and outlining the strategy for 2026. 👉 The overall message is that the company has strengthened its foundation and is entering an "increasingly attractive phase of its evolution."

• 2025 Performance: The CEO noted that 2025 was a "strong year," citing improved commercial performance, disciplined operational execution, and portfolio optimization.
• Consistency: This represents the third consecutive year the company met or exceeded its financial guidance, which the CEO highlights as evidence of a stable operating model.
• Future Focus: Moving forward, Bioventus plans to accelerate top-line growth while simultaneously expanding profitability. This will be achieved by investing in higher growth areas of the portfolio and leveraging strong operating leverage.

📅 Annual Meeting Logistics & Voting Details 🗳️

This section provides all the practical details for shareholders, addressing how, when, and where they need to cast their votes. 👉 Shareholders must pay close attention to the deadlines and their voting rights to ensure their shares are represented.

• Record Date: The list of eligible stockholders is set by the Record Date: April 6, 2026.
• Stockholder Ownership: As of the Record Date, there were 67,638,295 shares of Class A common stock and 15,786,737 shares of Class B common stock outstanding. These two classes combined represent the total voting power.
• Voting Method: Shareholders are strongly encouraged to vote their shares in advance, regardless of whether they plan to attend. Voting can be done via Internet (www.virtualshareholdermeeting.com/BVS2026), telephone, or by mail.
• Key Deadlines: The latest date to submit a proxy via mail or voting instruction card is the close of business on Tuesday, June 2, 2026.

👑 Board Leadership and Governance Structure 🌐

This topic explains who manages the company and how the board structure has been organized. 👉 The Board has formalized a structure that separates the Chairperson role from the CEO role, which the company believes enhances governance.

• Leadership Separation: Currently, the roles are separate: William A. Hawkins serves as the Chairperson of the Board (a position he has held since September 2020), while Robert E. Claypoole serves as the President and CEO.
• Rationale: The Board determined that separating these roles allows Mr. Claypoole to focus on the day-to-day business operations, and allows Mr. Hawkins to focus specifically on Board-related matters.
• Board Oversight: The Board has delegated oversight of various risks to specialized committees (see below), ensuring comprehensive governance.

👨‍⚖️ Committee Oversight and Internal Controls ✅

The Board of Directors doesn't handle all responsibilities itself; instead, it uses specialized committees to monitor specific areas of risk and operation. 👉 This separation of duties is a standard sign of a well-governed, mature public company.

• Audit and Risk Committee: This committee oversees the company’s enterprise risk assessment and management processes, including financial and cybersecurity risks.
• Compensation Committee: This committee is responsible for assessing and monitoring any compensation policies that might encourage excessive risk-taking.
• Compliance, Ethics and Culture Committee: This committee oversees legal, compliance, and regulatory risks to ensure adherence to rules.
• Nominating and Corporate Governance Committee: This committee is responsible for the search for qualified director candidates and reviewing the Board’s structure.

🌟 Electing the Board of Directors 🧑‍💼

This section covers the first major proposal: the election of the directors who will guide the company for the next period. 👉 Stockholders will vote to elect twelve directors who will serve until the 2027 Annual Meeting.

• Board Class Structure: The company has amended its charter to phase out the classified Board structure, moving to an annual election of all directors starting with this meeting.
• Vote Required: The proposal requires a plurality of votes, meaning the twelve nominees receiving the highest number of "FOR" votes will be elected.
• Director Nominees: The Board unanimously recommends voting FOR all twelve director nominees.
  • William A. Hawkins: Chairperson, notable for his experience as CEO of Immucor, Inc., and serving on boards like Biogen Inc.
  • John A. Bartholdson: Co-founder and Partner of Juniper Investment Company, bringing deep experience in private and public equity investments.
  • Robert E. Claypoole: President and CEO, bringing extensive global experience from Mölnlycke Health Care.
  • Other nominees include Patrick J. Beyer, Ajay Dhankhar, Mary Kay Ladone, Michelle McMurry-Heath, Guido J. Neels, Guy P. Nohra, Susan M. Stalnecker, and Martin P. Sutter.

⚖️ Ratifying the Independent Auditor 📊

This addresses the second major proposal: approving the company's external accountant. 👉 Shareholder ratification of the auditor is considered a best practice in corporate governance, even if it is not strictly required.

• The Appointment: The Audit and Risk Committee has appointed Grant Thornton as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Rationale for Vote: Although the ratification is not mandatory, the Board values the opinion of its stockholders, and Grant Thornton also served as the company’s auditor for the fiscal year ended December 31, 2025.
• Auditor Independence: Grant Thornton confirms that it has no financial interest in Bioventus other than its role as the company’s auditor.

💰 Compensation and Equity Plans 💵

This section details how the company pays its executives and how much equity (stock options/RSUs) is reserved for future payouts. 👉 The document shows the current scale of equity compensation and the sources of funds available for these incentives.

• Total Compensation Plan Size: As of December 31, 2025, the total equity compensation plan covers 7,599,261 securities.
• Existing Obligations: Of those, 6,226,186 securities are available to be issued upon exercise of outstanding options and rights.
• Reserved Shares: There are 13,129,209 securities remaining available for future issuance under equity compensation plans.
• Specific Programs: These plans include the 2021 Equity Incentive Plan, the 2021 Employee Stock Purchase Plan (ESPP), and the 2023 Retention Equity Award Plan.
• Key Detail: The plan notes that the shares reserved under the 2021 Incentive Plan will automatically increase on January 1 of each calendar year from January 1, 2022 through January 1, 2031, by a percentage of the outstanding shares.

📝 Policies and Compliance Rules 🛡️

Companies must adhere to strict legal rules regarding conflicts of interest and executive conduct. This section outlines three key policies the Board has put in place. 👉 These policies protect the company and its shareholders from illegal or questionable financial actions by executives.

• Code of Compliance and Ethics: The company maintains a written Code of Compliance and Ethics that applies to all directors, officers, and employees.
• Insider Trading Policy: This policy strictly prohibits any insider (directors, officers, etc.) from engaging in transactions designed to hedge or offset any potential decrease in the market value of the company's securities.
• Compensation Recovery Policy (Clawbacks): Adopted in September 2023 to comply with Dodd-Frank rules, this policy requires the company to seek the return or forfeiture of compensation if a future financial report must be restated due to material noncompliance.

💼 Executive Officers and Fees 📋

This section provides the key personnel and the costs associated with running the company's financial oversight. 👉 It is crucial to know who the executive team is and how much it costs to audit the books.

• Executive Team (as of April 22, 2026):
  • Robert E. Claypoole (Age 54): President, CEO, and Director.
  • Mark Singleton (Age 57): Senior Vice President and CFO.
  • Anthony D’Adamio (Age 65): Senior Vice President and General Counsel.
  • Katrina Church (Age 64): Senior Vice President and Chief Compliance Officer.
• Auditor Fees: The fees paid to Grant Thornton for audit services show an increase:
  • 2025 Audit Fees: $2,247 (in 000s).
  • 2024 Audit Fees: $1,832 (in 000s).

🧠 The Analogy 🧩

Imagine the company is a complex race car. 🏎️ The Proxy Statement is like the annual safety and strategy inspection report. It doesn't tell you how fast the car ran last year (that's the 10-K), but it shows you who is driving (the Directors), who is building the engine (the Executives), and whether all the necessary safety protocols and financial checks are in place (the Policies and Auditor approvals). It's checking the governance so that the company can run smoothly next year.

🧩 Final Takeaway 🔑

The Board is guiding Bioventus toward an accelerating growth phase, leveraging stable core products and focused investments in advanced technologies. Shareholders should focus their attention on the proposed slate of directors and the mechanisms governing executive pay and corporate compliance.